or Try an Advanced Search...

    Human Monoclonal Antibodies Stocks List

    Symbol Grade Name % Change
    XOMA A XOMA Corporation 0.60
    REGN F Regeneron Pharmaceuticals, Inc. 0.64
    VCNX F Vaccinex, Inc. 5.73
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Antibodies Immunology Monoclonal Antibodies Antibody Biotechnology Cardiovascular Disease Clinical Development Immune System Infectious Diseases Medicine Non Small Cell Lung Cancer Small Cell Lung Cancer Vascular Disease Acne Allergy Angiogenesis Antibody Product Asthma Atopic Dermatitis Autoimmune Disorders

    Related ETFs - A few ETFs which own one or more of the above listed Human Monoclonal Antibodies stocks.

    Symbol Grade Name Weight
    BBH D Market Vectors Biotech ETF 8.14
    IBB C iShares Nasdaq Biotechnology Index Fund 7.21
    IBBQ D Invesco Nasdaq Biotechnology ETF 6.52
    FPX B First Trust IPOX-100 Index Fund 5.71
    CANC C Tema Oncology ETF 5.42
    View all Human Monoclonal Antibodies ETFs...
    Compare ETFs
    Compare BBH to IBB Compare IBB to CANC Compare IBBQ to CANC

        Human Monoclonal Antibodies Stocks Recent News

        Date Stock Title
        Nov 1 REGN What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?
        Nov 1 REGN Regeneron Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
        Nov 1 REGN Regeneron: Investors In Panic Mode On Increased Eylea Fears
        Nov 1 REGN Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
        Nov 1 REGN Regeneron Pharmaceuticals Inc (REGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ...
        Nov 1 REGN Q3 2024 Regeneron Pharmaceuticals Inc Earnings Call
        Oct 31 REGN Regeneron Pharmaceuticals files automatic mixed securities shelf
        Oct 31 REGN Eylea headwinds said to be behind Regeneron’s post-Q3 plunge
        Oct 31 REGN Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
        Oct 31 REGN Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript
        Oct 31 REGN Regeneron down 10% despite top and bottom line beats
        Oct 31 VCNX Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
        Oct 31 REGN Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom
        Oct 31 REGN Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
        Oct 31 REGN REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
        Oct 31 REGN Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
        Oct 31 REGN Regeneron beats results estimates on demand for eczema treatment, eye drug
        Oct 31 REGN Regeneron: Q3 Earnings Snapshot
        Oct 31 REGN Regeneron Pharmaceuticals Non-GAAP EPS of $12.46 beats by $0.75, revenue of $3.72B beats by $50M
        Oct 31 REGN Regeneron Reports Third Quarter 2024 Financial and Operating Results
        Related Industries: Biotechnology
        Related Stock Lists: Antibodies Immunology Monoclonal Antibodies Antibody Biotechnology Cardiovascular Disease Clinical Development Immune System Infectious Diseases Medicine Non Small Cell Lung Cancer Small Cell Lung Cancer Vascular Disease Acne Allergy Angiogenesis Antibody Product Asthma Atopic Dermatitis Autoimmune Disorders
        Human Monoclonal Antibodies

        Human monoclonal antibodies are laboratory-produced proteins that are designed to mimic the antibodies naturally produced by the human immune system. They are created by cloning a single antibody-producing B-cell, which produces identical copies of the same antibody. These antibodies are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases.

        Browse All Tags